Ben Scent
December 12, 2022 | Daily Business Review
Dealmakers in Last-Minute $70B M&A Rush Before HolidaysBiotech giant Amgen is leading the flurry of transactions, saying it will buy Horizon Therapeutics for $28 billion to add drugs for rare disorders.
By Ben Scent and Dinesh Nair
3 minute read
Trending Stories
- 1NJ Supreme Court Clarifies Affidavit of Merit Requirement for Doctor With Dual Specialties
- 2Whether to Choose State or Federal Court in a Case Involving a Franchise?
- 3Am Law 200 Firms Announce Wave of D.C. Hires in White-Collar, Antitrust, Litigation Practices
- 4K&L Gates Files String of Suits Against Electronics Manufacturer's Competitors, Brightness Misrepresentations
- 5'Better of the Split': District Judge Weighs Circuit Divide in Considering Who Pays Decades-Old Medical Bill
